All you need to get started with ETF selection and analysis. Create your account now →
Help us improve your experience. Please confirm your investor type:
ETF What's Up
Don’t Miss a Move in the ETF Market
Sign up and keep track of everything that moved the ETF industry this week. From new launches to regulatory shifts across the Atlantic.
2639
JP3049310000
2639 ETF · Global X Japan Bio & Med Tech ETF
The 2639 Exchange Traded Fund (ETF) is provided by Global X. It is built to track an index: FactSet Japan Bio & Med Technologies Index. The 2639 ETF provides physical exposure, so by buying it you actually own parts of all the underlying holdings. This share class generates a stream of income by distributing dividends.
Last update Yesterday at 12:00 AM UTC
LIVE
CLOSED
This fund is part ofJapan Blended Cap1M perf.-7.26%
Last price
¥1,740
1M perf.
-0.08%
1M flows
N/A
AuM
€5.4M
E/R
0.649%
Rating
Not rated
ESG Consensus®
2639
¥1,740
Performance & flows
Segment for quartile rank
January 5, 2026 → April 1, 2026
Create a free account to view the flows graph
2639
¥1,754.46
+2.83%
Japan Blended Cap
+4.03%
Historic performance and flows
| 1M | 3M | 1Y | 3Y | 5Y | MTD | QTD | YTD | ||
|---|---|---|---|---|---|---|---|---|---|
| Perf. | -0.08%  | +2.83%  | +10.16%  | +15.96% | N/A | +4.26% | +4.26% | +3.87% | |
| Flows |
Key fund info
Segment for quartile rank
This ETF's jurisdiction country is not in your region (Europe and Middle East) ·
Main characteristics
More details
NAV
4/1/2026
¥1,754.46
1D NAV change
+4.26%
Dividend policy
Replication method
Direct (Physical)
Replication model
Optimized sampling
No. of holdings
N/A
Inception date
6/23/2021
Jurisdiction
Japan
Distribution
Japan
Legal structure
Open-end Fund
Base currency
JPY
Dividend distribution
Trailing 12-month distr. yield
Distribution frequency
Last distribution
Create a free account to view dividend distribution
Classification
Product type
Benchmark
FactSet Japan Bio & Med Technologies Index
Asset class
Factors
N/A
Investment strategy
Global X Japan Bio & Med Tech ETF is an exchange-traded fund incorporated in Japan. The fund's objective is to provide investment results that correspond to the performance of FactSet Japan Bio & Med Technologies Index (PR).
Tax optimisation
PEA
France
UK Reporting Status
United Kingdom
Create a free Trackinsight Essentials account to unlock insights
Access exclusive metrics and features to support your investment decisions.
Built for professionals: access exclusive fund metrics and selection tools in Trackinsight Enterprise.
Enterprise Fund page features include:
Legal documents
Powerful buy-list integration
Fund data exports
Advanced risk metrics
Advanced replication analysis
Advanced exposure look-through
Upload your own internal metrics
Custom data feature
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseAdvertisement
Risk profile
Segment for quartile rank
Historical risk/return profile
| 3M | 1Y | 3Y | 5Y | |
|---|---|---|---|---|
| Returns | +2.83% | +10.16% | +15.96% | N/A |
| Volatility | ||||
| Perf./Volatility | ||||
| Max drawdown |
Create a free account to view risk/return table
Synthetic Risk and Reward Indicator (SRRI)
UCITS
N/A
PRIIPS
N/A
More exposure metrics are available, exclusively in Trackinsight Enterprise
Exposure
Countries
Unavailable
100.00%
Sectors
Unavailable
100.00%
Diversification
This fund does not provide direct exposure to underlying securities.
Top 15 holdings
0
This fund does not provide direct exposure to underlying securities
More risk metrics are available, exclusively in Trackinsight Enterprise
Sustainability
Integrates ESG criteria
No
SDG
More sustainability metrics are available, exclusively in Trackinsight Enterprise
Replication
Trackinsight replication rating:
Not rated
Replication quality
Calculated over 12m, as of March 31, 2026
Tracking error
Tracking difference
Replication information
Index
FactSet Japan Bio & Med Technologies Index (PR) - JPY
Index ticker
FDSBMTP Index
Index dividend policy
GTR
Replication method
Replication model
More replication analysis are available, exclusively in Trackinsight Enterprise
Issuer
Global X
Global X ID Card
Number of funds
486
Total AuM
€134.2B
Expense ratio range
0.02% - 2.06%
Average expense ratio
0.5798%
Top 5 funds by Global X
| AuM | ||
|---|---|---|
PAVE | Global X U.S. Infrastructure Development ETF | €10.19B |
SHLD | Global X Defense Tech ETF | €7.33B |
QYLD | Global X Nasdaq 100 Covered Call ETF | €7.05B |
AIQ | Global X Artificial Intelligence & Technology ETF | €6.39B |
COPX | Global X Copper Miners ETF | €5.93B |
Frequently asked questions about 2639
What does Global X Japan Bio & Med Tech ETF, 2639, invest in?
2639 is a Passive ETF. This ETF provides exposure to Japanese Equities.
Which benchmark or index does 2639 replicate?
2639 tracks the FactSet Japan Bio & Med Technologies Index (PR) - JPY, through a optimized sampling replication method.
What is the Total Expense ratio (TER) of 2639?
2639 carries a total expense ratio (TER) of 0.649%, indicating the annual cost for holding the fund.
When was 2639 launched?
2639 was introduced to the market on June 23, 2021. It trades on Japan
Who is the ETF issuer of 2639?
Global X Japan Bio & Med Tech ETF, 2639, is provided by Global X. Learn more about Global X here.
What is the current assets under management (AUM) of 2639?
2639 oversees €5.4M in assets as of April 1, 2026.
How has 2639 performed lately?
Based on data from April 1, 2026, 2639 returned -0.08% over the past month, 2.83% over the last three months and 3.87% year-to-date.
What are the latest inflows or outflows for 2639?
As of April 1, 2026, 2639 recorded net flows of +€286K year-to-date.
Does 2639 distribute dividends?
2639 follows a distributing dividend policy, meaning it pays out income to investors. As of April 1, 2026, its 12-month trailing yield was 1.25%.
What is the base currency of 2639?
The base currency of 2639 is JPY.
Advertisement
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy | Cookie policy | | Terms of use | Imprint
Privacy policy | Cookie policy | | Terms of use | Imprint
